HC Wainwright Has Optimistic View of Trevena FY2024 Earnings

Trevena, Inc. (NASDAQ:TRVN) – Investment analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of Trevena in a report issued on Thursday, November 14th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings per share of ($23.04) for the year, up from their previous estimate of ($32.25). HC Wainwright has a “Neutral” rating and a $5.00 price objective on the stock. The consensus estimate for Trevena’s current full-year earnings is ($23.04) per share. HC Wainwright also issued estimates for Trevena’s Q4 2024 earnings at ($2.50) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.31) EPS.

Separately, StockNews.com initiated coverage on Trevena in a report on Tuesday. They set a “sell” rating on the stock.

Trevena Stock Up 1.2 %

Trevena stock opened at $1.70 on Monday. Trevena has a 52 week low of $1.13 and a 52 week high of $19.23. The company’s 50 day moving average price is $2.86 and its two-hundred day moving average price is $5.45. The stock has a market cap of $1.46 million, a P/E ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million for the quarter.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.